Position in FATE
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$55,401
+$24,075 QoQ
Shares Held
46,168
+44.4% QoQ
Ownership
0.040%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2024
9 quarters on record
Voting authority
Sole 1.0136891353318316.ToString("F0")%
Shared 0.ToString("F0")%
None 98.98631086466817.ToString("F0")%
Common Shares in FATE Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026Focus Partners Wealth holds $172,241,737 across 69 Biotechnology names. FATE ranks #51 (0.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
131,435 | $58,690,984 | |
| 2 | CELC |
Celcuity Inc.
|
233,390 | $26,639,134 | |
| 3 | REGN |
Regeneron Pharmaceuticals, Inc.
|
16,441 | $12,702,974 | |
| 4 | IONS |
Ionis Pharmaceuticals Inc
|
165,544 | $12,430,698 | |
| 5 | HALO |
Halozyme Therapeutics, Inc.
|
169,286 | $10,940,954 | |
| 6 | INCY |
Incyte Corp
|
116,075 | $10,924,979 | |
| 7 | RPRX |
Royalty Pharma plc
|
116,250 | $5,576,512 | |
| 8 | EXEL |
Exelixis, Inc.
|
107,776 | $4,622,512 |
All Filings in FATE
Export CSV
9 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $55,401 | 46,168 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $31,326 | 31,966 | Shares | Sole | 2026-02-13 | |
| 2025-09-30 | $15,293 | 12,138 | Shares | Sole | 2025-11-14 | |
| 2025-06-30 | $36,641 | 32,716 | Shares | Sole | 2025-08-14 | |
| 2025-03-31 | $23,858 | 30,201 | Shares | Sole | 2025-05-20 | |
| 2024-12-31 | $39,918 | 24,193 | Shares | Sole | 2025-05-29 | |
| 2024-09-30 | $82,785 | 23,653 | Shares | Sole | 2024-11-14 | |
| 2024-06-30 | $78,411 | 23,906 | Shares | Sole | 2024-08-15 | |
| 2024-03-31 | $173,613 | 23,653 | Shares | Sole | 2024-05-16 | |
| No filing history on record for this holder in this stock. | ||||||